Together, we can make a footprint in molecular imaging

It's about patient care

As a proven leader in PET (Positron Emission Tomography) radiopharmaceutical manufacturing and distribution, Cardinal Health is in a unique position to gather and share information with the national PET community and its patients.

Cardinal Health has a proven track record in leadership, operating the largest US radiopharmacy network.  We have more than 150 nuclear pharmacies serving more than 7,000 hospitals and clinics daily.  One hundred of these pharmacies are PET enabled that distribute 18F FDG to more than 90% of PET facilities in the United States. We continue to grow our network with additional PET manufacturing cyclotrons to meet our customers’ needs.

Cardinal Health PET FoundationsSM is a comprehensive marketing and educational website designed to build awareness and educate physicians, clinicians and the healthcare community on the clinical efficacy and appropriate uses of PET.

  • Patients needing information to prepare for a PET scan
  • Administrators wanting to learn more about the PET modality and its indications as well as utilize marketing materials and tools to promote awareness and grow their practice
  • Technologists wanting to complete educational requirements

Thank you for making Cardinal Health your partner of choice – and for joining Cardinal Health in our commitment to advance the diagnosis and treatment of disease through the use of radiopharmaceuticals. 


eNews updates

Receive the latest in reimbursement news by subscribing to our email list.

Subscribe

View recent eNews


2012 Reimbursement Changes

Let Cardinal Health keep you updated on the latest PET reimbursement rules and guidelines. Learn about the Final Changes to the Hospital Outpatient Prospective Payment System (HOPPS) and 2012 Payment Rates. 

Read the article.

Visit the reimbursement section for more information, reimbursement guides, and other resources.

Patient brochures
18F NAF

Bone metastasis is the most common malignant bone tumor and often occurs in patients with solid tumor cancers such as breast, lung and prostate. Since the diagnosis of the metastatic bone disease is critical, it is absolutely vital that the diagnosis be correct with the appropriate method.

Learn more